Cargando…
Humoral efficacy of the third SARS-CoV-2 vaccine dose in Multiple Sclerosis subjects undergoing different disease-modifying therapies
BACKGROUND: It remains unclear how vaccine doses and combinations of vaccination and infection affect the magnitude and quality of immune responses, particularly against novel SARS-CoV-2 variants in subjects with immune-related disorders, such as people with multiple sclerosis (pwMS). Several studie...
Autores principales: | Maniscalco, Giorgia Teresa, Liotti, Antonietta, Ferrara, Anne Lise, Prestipino, Elio, Salvatore, Simona, Di Battista, Maria Elena, Moreggia, Ornella, Di Giulio Cesare, Daniele, Vastano, Roberta, Belardo, Martina, Napolitano, Massimo, Ranieri, Angelo, Longo, Katia, Andreone, Vincenzo, De Rosa, Veronica |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9595409/ https://www.ncbi.nlm.nih.gov/pubmed/36544318 http://dx.doi.org/10.1016/j.msard.2022.104371 |
Ejemplares similares
-
Long term persistence of SARS-CoV-2 humoral response in multiple sclerosis subjects
por: Maniscalco, Giorgia Teresa, et al.
Publicado: (2022) -
Three Doses of COVID-19 Vaccines: A Retrospective Study Evaluating the Safety and the Immune Response in Patients with Multiple Sclerosis
por: Maniscalco, Giorgia Teresa, et al.
Publicado: (2023) -
Interferon Beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects
por: Maniscalco, Giorgia Teresa, et al.
Publicado: (2022) -
The Safety Profile of COVID-19 Vaccines in Patients Diagnosed with Multiple Sclerosis: A Retrospective Observational Study
por: Maniscalco, Giorgia Teresa, et al.
Publicado: (2022) -
Severe Multiple Sclerosis Relapse After COVID-19 Vaccination: A Case Report
por: Maniscalco, Giorgia T., et al.
Publicado: (2021)